Eli Lilly and Co. missed Wall Street estimates for sales of its keenly-watched drug Mounjaro as well as older diabetes treatment, overshadowing a better-than-expected 2023 profit forecast.

The FDA granted Eli Lilly’s Jaypirca (pirtobrutinib) accelerated approval for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL), the company announced Friday.

The company plans to expand its manufacturing capacity at the Research Triangle Park facility in North Carolina to support increased demand for its key diabetes drugs. It has been struggling to meet high demand for the drugs Trulicity and Mounjaro, especially due to production of multiple dosage forms for each of them.

Companies are increasingly arguing that it is no longer possible to justify the UK’s “voluntary scheme” to global boardrooms and investors as repayment rates in 2023 have surged to 26.5% of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement.

California is suing the United States’ leading insulin makers and pharmacy benefit managers, accusing them of using their market power to overcharge patients for the life-saving drug, the state’s attorney general announced on Thursday.

Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.

The company has entered into a multi-target partnership with Sosei Group to discover, develop and commercialize compounds targeting novel G protein-coupled receptor (GPCR) targets in diabetes and metabolic diseases.

Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.

The drug is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.

Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.